Pharmacogenomics and Heart Failure Patients on Carvedilol | ||||
| Benha Medical Journal | ||||
| Article 1, Volume 36, Issue 3, March 2020, Page 77-88 PDF (996.19 K) | ||||
| Document Type: Review Article | ||||
| DOI: 10.21608/bmfj.2020.75818 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| Aya Mohamed Bahgat Awad | ||||
| Pharmacology department, faculty of medicine, zagazig university | ||||
| Abstract | ||||
| Pharmacogenomics is a science of how genes affect person’s response to drugs. This field integrates pharmacology and genomics for development of safe and effective medications which tailored to person’s genetic makeup. Genes are instructions, written in deoxyribonucleic acid (DNA), for constructing protein molecules. Diverse people can have various versions of the same gene.Cardiovascular diseases remain number one killer of mankind, and heart failure (HF) pays a fair contribution to this spectrum of diseases.Many options are available for the drug treatment in HF patients, with recent trends depending mainly on beta blockers (BBs) and angiotensin-converting-enzyme inhibitor (ACEIs) in addition to diuretics.BBs exert their effects by antagonizing the activation of β-ARs, and α-ARs in case of carvedilol. Variations of these receptors can be involved in how HF patients with various genotypes respond to BBs. Therefore, we discuss some of the most commonly described single nucleotide polymorphisms (SNPs) in this review of literatures. | ||||
|
Statistics Article View: 510 PDF Download: 679 |
||||
